US Stocks Edge Lower; Fastenal Posts Upbeat Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Should l Buy DARE?
Source: Benzinga
Market Overview: U.S. stocks experienced slight declines with the Dow Jones down 0.1%, while energy stocks fell by 0.7%. Fastenal reported better-than-expected earnings, and several companies saw significant stock price increases, including Sonnet BioTherapeutics and Daré Bioscience.
Global Market Trends: European shares mostly decreased, with the eurozone's STOXX 600 down 0.4%, while Asian markets showed mixed results. No major economic reports were scheduled for release today.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DARE
Wall Street analysts forecast DARE stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.510
Low
8.00
Averages
10.00
High
12.00
Current: 1.510
Low
8.00
Averages
10.00
High
12.00
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Daré Bioscience Q4 2025 Earnings Call Insights
- Product Launch Progress: Daré Bioscience's DARE to PLAY topical sildenafil cream began pre-fulfillment prescribing in February 2026 and is now available in all 50 states, marking a significant step in the company's strategic focus on women's health, which is expected to create substantial shareholder value.
- Strong Financial Position: As of year-end 2025, the company reported approximately $24.7 million in cash and cash equivalents and $3.4 million in working capital, demonstrating financial resilience in R&D and marketing efforts, providing a solid foundation for future product launches.
- Pipeline Update: The Phase III trial for Ovaprene is anticipated to complete enrollment in 2026, with data readout expected in 2027, while DARE-HPV is advancing to Phase II clinical studies in 2026, indicating ongoing progress in the company's commitment to women's health and potential for innovative products.
- Market Strategy Optimization: The company is leveraging a digitally native commercial model with Medvantx for product fulfillment and plans to enhance market penetration through strategic distribution partnerships, ensuring a competitive edge in a rapidly evolving market.
See More
Dare Bioscience Reports Strong FY Earnings Beat
- Strong Earnings Performance: Dare Bioscience reported a FY GAAP EPS of -$1.20, beating expectations by $0.45, indicating improvements in financial management and increased market demand for its products.
- Significant Revenue Growth: The company achieved revenues of $1.03 million, a staggering 10200% increase year-over-year, surpassing expectations by $0.26 million, which highlights the strong market performance and acceptance of its offerings.
- Healthy Cash Position: As of December 31, 2025, Dare Bioscience had approximately $24.7 million in cash and cash equivalents, along with $3.4 million in working capital, demonstrating robust financial management and providing ample support for future growth initiatives.
- Optimistic Market Outlook: With significant improvements in revenue and cash flow, Dare Bioscience's competitiveness in the biopharmaceutical sector is strengthened, likely attracting more investor interest and driving stock price appreciation.
See More
Dare Bioscience Reports FY EPS Beat
- Earnings Performance: Dare Bioscience reported a FY GAAP EPS of -$1.20, beating expectations by $0.45, indicating improvements in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, Dare had approximately $24.7 million in cash and cash equivalents, suggesting a relatively healthy liquidity position that supports future operations and R&D efforts.
- Working Capital: With working capital around $3.4 million, although low, it allows for basic operations, reflecting the company's cautious strategy in resource allocation.
- Market Reaction: The financial data from Dare Bioscience has attracted market attention, with investors showing optimism about its future prospects, potentially driving stock price increases and enhancing market confidence.
See More
Dare Bioscience to Announce FY Earnings Results
- Earnings Announcement Date: Dare Bioscience is set to release its FY earnings results on March 26 after market close, with market participants keenly awaiting the performance to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$1.65, reflecting a staggering 243.8% year-over-year decline, indicating significant challenges in the company's profitability.
- Revenue Expectations: The consensus revenue estimate is $0.77 million, representing a remarkable 7600% year-over-year increase, suggesting substantial improvement in revenue growth, potentially driven by new products or market expansion.
- Historical Performance Review: Over the past year, Dare Bioscience has beaten EPS estimates 50% of the time and revenue estimates 50% of the time, highlighting its performance volatility and adaptability in the market.
See More
Daré Bioscience Receives FDA Clearance for HPV Treatment Study
- FDA Clearance Milestone: Daré Bioscience's DARE-HPV has received IND approval from the FDA, allowing the company to initiate a planned Phase 2 clinical study aimed at evaluating the drug as a potential treatment for persistent high-risk HPV infection, addressing a significant gap in women's health treatment options.
- Innovative Treatment Approach: DARE-HPV is a non-surgical, localized self-administered therapy designed to target the HPV virus directly, potentially transforming the current monitoring-focused treatment paradigm and alleviating the economic and psychological burdens on women during the waiting period for the virus to clear.
- Funding Support and Market Need: The program is backed by a $10 million contract from the Advanced Research Projects Agency for Health (ARPA-H), with $6.5 million received to date, highlighting the emphasis on and investment potential in women's health.
- Clinical Study Outlook: The planned Phase 2 study will assess the safety and antiviral activity of DARE-HPV, and if successful, it will provide women with new treatment options, significantly changing the management of high-risk HPV infections and carrying important social and economic implications.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Daré Bioscience Q4 2025 Earnings Call Insights
- Product Launch Progress: Daré Bioscience's DARE to PLAY topical sildenafil cream began pre-fulfillment prescribing in February 2026 and is now available in all 50 states, marking a significant step in the company's strategic focus on women's health, which is expected to create substantial shareholder value.
- Strong Financial Position: As of year-end 2025, the company reported approximately $24.7 million in cash and cash equivalents and $3.4 million in working capital, demonstrating financial resilience in R&D and marketing efforts, providing a solid foundation for future product launches.
- Pipeline Update: The Phase III trial for Ovaprene is anticipated to complete enrollment in 2026, with data readout expected in 2027, while DARE-HPV is advancing to Phase II clinical studies in 2026, indicating ongoing progress in the company's commitment to women's health and potential for innovative products.
- Market Strategy Optimization: The company is leveraging a digitally native commercial model with Medvantx for product fulfillment and plans to enhance market penetration through strategic distribution partnerships, ensuring a competitive edge in a rapidly evolving market.
See More
Dare Bioscience Reports Strong FY Earnings Beat
- Strong Earnings Performance: Dare Bioscience reported a FY GAAP EPS of -$1.20, beating expectations by $0.45, indicating improvements in financial management and increased market demand for its products.
- Significant Revenue Growth: The company achieved revenues of $1.03 million, a staggering 10200% increase year-over-year, surpassing expectations by $0.26 million, which highlights the strong market performance and acceptance of its offerings.
- Healthy Cash Position: As of December 31, 2025, Dare Bioscience had approximately $24.7 million in cash and cash equivalents, along with $3.4 million in working capital, demonstrating robust financial management and providing ample support for future growth initiatives.
- Optimistic Market Outlook: With significant improvements in revenue and cash flow, Dare Bioscience's competitiveness in the biopharmaceutical sector is strengthened, likely attracting more investor interest and driving stock price appreciation.
See More
Dare Bioscience Reports FY EPS Beat
- Earnings Performance: Dare Bioscience reported a FY GAAP EPS of -$1.20, beating expectations by $0.45, indicating improvements in financial management despite still being in a loss position.
- Cash Position: As of December 31, 2025, Dare had approximately $24.7 million in cash and cash equivalents, suggesting a relatively healthy liquidity position that supports future operations and R&D efforts.
- Working Capital: With working capital around $3.4 million, although low, it allows for basic operations, reflecting the company's cautious strategy in resource allocation.
- Market Reaction: The financial data from Dare Bioscience has attracted market attention, with investors showing optimism about its future prospects, potentially driving stock price increases and enhancing market confidence.
See More
Dare Bioscience to Announce FY Earnings Results
- Earnings Announcement Date: Dare Bioscience is set to release its FY earnings results on March 26 after market close, with market participants keenly awaiting the performance to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$1.65, reflecting a staggering 243.8% year-over-year decline, indicating significant challenges in the company's profitability.
- Revenue Expectations: The consensus revenue estimate is $0.77 million, representing a remarkable 7600% year-over-year increase, suggesting substantial improvement in revenue growth, potentially driven by new products or market expansion.
- Historical Performance Review: Over the past year, Dare Bioscience has beaten EPS estimates 50% of the time and revenue estimates 50% of the time, highlighting its performance volatility and adaptability in the market.
See More
Daré Bioscience Receives FDA Clearance for HPV Treatment Study
- FDA Clearance Milestone: Daré Bioscience's DARE-HPV has received IND approval from the FDA, allowing the company to initiate a planned Phase 2 clinical study aimed at evaluating the drug as a potential treatment for persistent high-risk HPV infection, addressing a significant gap in women's health treatment options.
- Innovative Treatment Approach: DARE-HPV is a non-surgical, localized self-administered therapy designed to target the HPV virus directly, potentially transforming the current monitoring-focused treatment paradigm and alleviating the economic and psychological burdens on women during the waiting period for the virus to clear.
- Funding Support and Market Need: The program is backed by a $10 million contract from the Advanced Research Projects Agency for Health (ARPA-H), with $6.5 million received to date, highlighting the emphasis on and investment potential in women's health.
- Clinical Study Outlook: The planned Phase 2 study will assess the safety and antiviral activity of DARE-HPV, and if successful, it will provide women with new treatment options, significantly changing the management of high-risk HPV infections and carrying important social and economic implications.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
